press release

Pictured: Future Fields Recombinant Human Prolactin, Fc Tag.

EDMONTON, Alberta, Canada – January 16, 2024 – Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protein production, proudly announces the launch of its Recombinant Human Prolactin. Containing a cleavable Fc-tag, Future Fields Recombinant Human Prolactin (PRL-Fc) is the first-ever prolactin protein derived from a commercial fruit fly expression system.

Prolactin, or PRL, is a hormone synthesized primarily by the pituitary gland and has multiple functions. Use cases of Future Fields’ Recombinant Human Prolactin include supporting research that addresses:

• Lactation insufficiency in breastfeeding mothers

• Improvement of breast milk composition

• Cultivated milk product R&D and production

• Specialized infant formulations by acting as a food ingredient

• Immune cell (dendritic cells, lymphocytes), mammary epithelial cell and neuronal cell research

• Cell protection during islet cell and liver transplantation

Key features and benefits of Future Fields’ Recombinant Human Prolactin include:

• Activity: Confirmed functionality using cell proliferation assays

• Uniqueness: Confirmed to be N-glycosylated

• Safety: Confirmed to be negative for mycoplasma and below threshold for endotoxin from Lot-to-Lot – suited for cell culture and preclinical applications

• Price: Product price that is lowest on the market, without compromising quality

Recombinant Human Prolactin represents the culmination of dedicated research and development, leveraging the latest advancements in Future Fields’ EntoEngine™ and downstream processes to create a high-quality recombinant human protein. Made in their bioreactor-free, green-certified lab, the launch furthers Future Fields’ commitment to building a future that does not compromise the health and viability of humanity and the planet.

Future Fields CEO, Matt Anderson-Baron, commented on the launch, stating, "We are thrilled to introduce our Recombinant Human Prolactin to the market. This product is a testament to our unwavering commitment to advancing our biomanufacturing platform and delivering sustainable, cost-effective solutions for researchers and scientists worldwide."

This product launch follows Future Fields’ CDMO service offering announcement in September 2023. Using fruit flies as ‘factories’ for therapeutic and research use only proteins, Future Fields continues to demonstrate the ability of the EntoEngine™ to produce stable, highly reproducible results at scale and at an affordable price.